IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution

摘要

Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with and ( / ) mutations are ongoing. Reports of / ‐mutated non–small cell lung cancers (NSCLCs), however, are limited.